Author

M. Ruella

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1

Frequent Co-Authors

L. Paruzzo· 2 shared A. Cozzone· 1 shared A. Neeser· 1 shared A. Romanov· 1 shared A. Thomas-Tikhonenko· 1 shared B. Cossette· 1 shared B. Goncalves· 1 shared C. D. Falkenstein· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

L. Paruzzo

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells

T. Grzywa, N. Mehta, B. Cossette, A. Romanov, L. Paruzzo, R. Ramasubramanian, A. Cozzone, D. Morgan, I. Sukaj, E. Bergaggio, R. Tannir, S. Kadauke, R. Myers, P. Yousefpour, G. Ghilardi, , D. J. Irvine

This study develops a method to generate optimized peptide ligands for CAR-T cell restimulation, demonstrating enhanced expansion and memory development in preclinical models.

bioRxiv · Apr 16, 2024 · PreprintBioengineering

Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

Z. Ang, L. Paruzzo, K. E. Hayer, C. Schmidt, M. Torres Diz, F. Xu, U. Zankharia, Y. Zhang, S. Soldan, S. Zheng, C. D. Falkenstein, J. P. Loftus, S. Y. Yang, M. Asnani, P. King Sainos, , A. Thomas-Tikhonenko

This study identifies alternative splicing of CD20 mRNA that generates translation-deficient isoforms, contributing to resistance to CD20-directed immunotherapies.

bioRxiv · Feb 19, 2023Immunology

Impaired tumor death receptor signaling drives resistance to CAR T cell therapy

N. Singh, O. Shestova, P. Ravikumar, K. Hayer, S. J. Hong, E. J. Orlando, K. T. Mueller, C. R. Good, S. L. Berger, O. Shalem, M. D. Weitzman, S. A. Grupp, C. H. June, S. Gill, M. Ruella

This study identifies impaired death receptor signaling as a driver of resistance to CAR T cell therapy in B-cell leukemia by showing its role in tumor survival and T cell dysfunction.

bioRxiv · May 5, 2019 · PreprintImmunology